<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2252">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131841</url>
  </required_header>
  <id_info>
    <org_study_id>SSGJ-302H-mBC-IIT-01</org_study_id>
    <nct_id>NCT05131841</nct_id>
  </id_info>
  <brief_title>Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC</brief_title>
  <official_title>A Multi-center, Randomized, Open-label Study on Pharmacokinetics, Safety, Efficacy, and Immunogenicity of Cipterbin Combined With Vinorelbine Injection Every Week or Every Three Weeks in the Treatment of Patients With HER2-positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Proswell Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare pharmacokinetics Index of Cipterbin combined with Vinorelbine Injection every week&#xD;
      or every three weeks in the treatment of patients with HER2-positive metastatic breast cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center, randomized, open-label study on pharmacokinetics, safety, efficacy, and&#xD;
      immunogenicity of Cipterbin combined with Vinorelbine Injection every week or every three&#xD;
      weeks in the treatment of patients with HER2-positive metastatic breast cancer. The main&#xD;
      purpose was to compare pharmacokinetics Index between two groups, secondly to observe safety,&#xD;
      efficacy, and immunogenicity&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>From enrollment to 21 days after the last dose administrate</time_frame>
    <description>Cmax after the last administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin</measure>
    <time_frame>From enrollment to 21 days after the last dose administrate</time_frame>
    <description>Cmin after the last administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>From enrollment to 21 days after the last dose administrate</time_frame>
    <description>AUC0-t after the last administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau</measure>
    <time_frame>From enrollment to 21 days after the last dose administrate</time_frame>
    <description>AUCtau after the last administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multiple sets of Cmax</measure>
    <time_frame>From enrollment to 21 days after the last dose administrate</time_frame>
    <description>Cmax after the first administration and the third administration in the three-week administration group and the seventh administration in the one-week administration group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple sets of Cmin</measure>
    <time_frame>From enrollment to 21 days after the last dose administrate</time_frame>
    <description>Cmin after the first administration and the third administration in the three-week administration group and the seventh administration in the one-week administration group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple sets of AUC0-t</measure>
    <time_frame>From enrollment to 21 days after the last dose administrate</time_frame>
    <description>AUC0-t after the first administration and the third administration in the three-week administration group and the seventh administration in the one-week administration group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple sets of AUCtau</measure>
    <time_frame>From enrollment to 21 days after the last dose administrate</time_frame>
    <description>AUCtau after the first administration and the third administration in the three-week administration group and the seventh administration in the one-week administration group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple sets of Tmax</measure>
    <time_frame>From enrollment to 21 days after the last dose administrate</time_frame>
    <description>Tmax after the first administration and the third administration in the three-week administration group and the seventh administration in the one-week administration group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety index</measure>
    <time_frame>From enrollment to 30 days after the last dose administrate</time_frame>
    <description>Adverse Events during the test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BOR</measure>
    <time_frame>From enrollment to death(for any reason),Until 24 months after the last subject left the administration group</time_frame>
    <description>Record the proportion of CR and PR in all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>From enrollment to death(for any reason),Until 24 months after the last subject left the administration group</time_frame>
    <description>CR/PR/SD accounted for the proportion of all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>From enrollment to death(for any reason),Until 24 months after the last subject left the administration group</time_frame>
    <description>Overall Survival of all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index</measure>
    <time_frame>From enrollment to 21 days after the last dose administrate</time_frame>
    <description>ADA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>One-week group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cipterbin combined with Vinorelbine Injection every week in the treatment of patients with HER2-positive metastatic breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Three-week group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cipterbin combined with Vinorelbine Injection every three weeks in the treatment of patients with HER2-positive metastatic breast cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cipterbin Combined With Vinorelbine</intervention_name>
    <description>Cipterbin combined with Vinorelbine Injection every week in the treatment of patients with HER2-positive metastatic breast cancer&#xD;
Cipterbin combined with Vinorelbine Injection every three weeks in the treatment of patients with HER2-positive metastatic breast cancer</description>
    <arm_group_label>One-week group</arm_group_label>
    <arm_group_label>Three-week group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 and ≤70 years old, female.&#xD;
&#xD;
          -  BMI index in the range of 19.0~28.0&#xD;
&#xD;
          -  ECOG≤1, and the expected os ≥3 months&#xD;
&#xD;
          -  Unresectable metastatic breast cancer diagnosed by histology or pathology that has&#xD;
             received one or more chemotherapy regimens.&#xD;
&#xD;
          -  HER2 overexpression is +++ by immunohistochemistry (IHC) or + by fluorescence&#xD;
             hybridization FISH.&#xD;
&#xD;
          -  At least one measurable lesion.&#xD;
&#xD;
          -  Sufficient organ function&#xD;
&#xD;
          -  Voluntarily signed an informed consent form.&#xD;
&#xD;
          -  Subjects with good compliance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Rapid disease progression or threaten important organs and require urgent replacement&#xD;
             therapy.&#xD;
&#xD;
          -  Undergone surgery within 28 days before treatment (except for biopsy)&#xD;
&#xD;
          -  Received radiotherapy within 21 days before the first study drug treatment or the side&#xD;
             effects of radiotherapy have not recovered to 0 or 1&#xD;
&#xD;
          -  Suffer from other serious uncontrolled diseases (such as epilepsy, liver failure,&#xD;
             kidney failure, etc.)&#xD;
&#xD;
          -  Suffered from other malignant tumors within 5 years before receiving the first study&#xD;
             drug treatment or at the same time.&#xD;
&#xD;
          -  Severely infected&#xD;
&#xD;
          -  Clear history of mental illness, or have a history of alcoholism or drug abuse.&#xD;
&#xD;
          -  Central nervous system metastasis or meningeal metastasis with clinical symptoms&#xD;
&#xD;
          -  Cardiac function left ventricular ejection fraction &lt; 50%&#xD;
&#xD;
          -  Obvious arrhythmia, myocardial ischemia, severe atrioventricular block, cardiac&#xD;
             insufficiency, severe heart valve Membrane disease patients&#xD;
&#xD;
          -  Poorly controlled hypertension&#xD;
&#xD;
          -  Patients with coagulopathy: INR or APTT ≥1.5×ULN&#xD;
&#xD;
          -  Allergic to the test drug or its excipients in the study treatment, or have a severe&#xD;
             allergic reaction to other monoclonal antibody drugs in the past&#xD;
&#xD;
          -  Pregnant or breastfeeding, or cannot take reliable contraceptive measures during the&#xD;
             trial and within 6 months after the end of the medication Giver&#xD;
&#xD;
          -  Have received a certain test drug in other interventional clinical trials, the&#xD;
             interval is less than 28 days or less than 5 half lives of the drug (whichever is&#xD;
             longer)&#xD;
&#xD;
          -  Have used a monoclonal antibody within 6 months before receiving the first study drug&#xD;
             treatment&#xD;
&#xD;
          -  Have received other drugs that may affect the pharmacokinetic results of the study&#xD;
             drug, the interval is less than 28 days or less than 5 half lives of the drug&#xD;
             (whichever is longer)&#xD;
&#xD;
          -  Have received organ transplants (including autologous/allologous stem cell&#xD;
             transplants) in the past&#xD;
&#xD;
          -  Other conditions judged by the investigator to be inappropriate for participating in&#xD;
             this trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Huang, chief doctor</last_name>
    <role>Study Director</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaojia Wang, PHD</last_name>
    <phone>86 13906500190</phone>
    <email>wxiaojia0803@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian Huang, chief doctor</last_name>
    <phone>86 13588048995</phone>
    <email>huang_jian22@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojia Wang</last_name>
      <phone>+86 13906500190</phone>
      <email>wxiaojia0803@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Cancer Hospital</investigator_affiliation>
    <investigator_full_name>wangxiaojia</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>HER2-positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data will be shared from the trial begin for 10 years</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>From the trial begin for 10 years</ipd_time_frame>
    <ipd_access_criteria>Every one</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

